ArticleJournal of immunotherapy (Hagerstown, Md. : 1997)2018
Brief Communication; A Heterologous Oncolytic Bacteria-Virus Prime-Boost Approach for Anticancer Vaccination in Mice.
Article in Journal of immunotherapy (Hagerstown, Md. : 1997), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Bacteria-based immunotherapy for cancer: a systematic review of preclinical studies.Frontiers in immunology · 2023Pooled it
- Antibiotic-mediated selection of randomly mutagenized and cytokine-expressing oncolytic viruses.Nature biomedical engineering · 2025Article
- Oncolytic VSV-IL-2 has enhanced anticancer vaccination adjuvant abilities.Journal for immunotherapy of cancer · 2025Article
- An Update on the Clinical Status, Challenges, and Future Directions of Oncolytic Virotherapy for Malignant Gliomas.Current treatment options in oncology · 2024Review
- Novel personalized cancer vaccine platform based on Bacillus Calmette-Guèrin.Journal for immunotherapy of cancer · 2021Article
- Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination.Nature communications · 2021Article
- Novel Protein-Based Vaccine against Self-Antigen Reduces the Formation of Sporadic Colon Adenomas in Mice.Cancers · 2021Article
- In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity.Journal for immunotherapy of cancer · 2021Article
- Clinical Experience and Recent Advances in the Development ofFrontiers in immunology · 2021Review
- Viral Nanoparticles: Cancer Vaccines and Immune Modulators.Advances in experimental medicine and biology · 2021Article
- Heterologous Prime Boost Vaccination Induces Protective Melanoma-Specific CD8Molecular therapy oncolytics · 2020Article
- Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Review
- Development and applications of oncolytic Maraba virus vaccines.Oncolytic virotherapy · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Anticancer vaccination is becoming a popular therapeutic approach for patients with cancers expressing common tumor antigens. One variation on this strategy is a heterologous virus vaccine where 2 viruses encoding the same tumor antigen are administered sequentially to prime and boost antitumor immunity. This approach is currently undergoing clinical investigation using an adenovirus (Ad) and the oncolytic virus Maraba (MRB). In this study, we show that Listeria monocytogenes can be used in place of the Ad to obtain comparable immune priming efficiency before MRB boosting. Importantly, the therapeutic benefits provided by our heterologous L. monocytogenes-MRB prime-boost strategy are superior to those conferred by the Ad-MRB combination. Our study provides proof of concept for the heterologous oncolytic bacteria-virus prime-boost approach for anticancer vaccination and merits its consideration for clinical testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.